Détails du produit
Synonyms
NCR1, LY94, CD335, NK-p46, hNKp46
Source
Cynomolgus NKp46, Llama IgG2b Fc Tag (NC1-C5255) is expressed from human 293 cells (HEK293). It contains AA Pro 22 - Arg 257 (Accession # Q95JB9-1).
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a llama IgG2b Fc tag at the C-terminus.
The protein has a calculated MW of 54.7 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
After reconstitution, this product is stable after storage at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Cynomolgus NKp46, Llama IgG2b Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA

Immobilized Cynomolgus NKp46, Llama IgG2b Fc Tag (Cat. No. NC1-C5255) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-NKp46 Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Natural cytotoxicity triggering receptor 1
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
3 Détails
- Étape de développement la plus élevée:
Phase 2 Clinical



















